An Endorsement of the Removal of Race From GFR Estimation Equations: A Position Statement From the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

National Kidney Foundation Kidney Disease Outcomes Quality Initiative

doi:10.1053/j.ajkd.2022.08.004

An Endorsement of the Removal of Race From GFR Estimation Equations: A Position Statement From the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

National Kidney Foundation Kidney Disease Outcomes Quality Initiative

Research output: Contribution to journal › Comment/debate

6 Scopus citations

Original language	English
Pages (from-to)	691-696
Number of pages	6
Journal	American Journal of Kidney Diseases
Volume	80
Issue number	6
DOIs	https://doi.org/10.1053/j.ajkd.2022.08.004
State	Published - Dec 2022
Externally published	Yes

Access to Document

10.1053/j.ajkd.2022.08.004

Cite this

@article{5441d7df7aee46d5ae40bb26c887d967,

title = "An Endorsement of the Removal of Race From GFR Estimation Equations: A Position Statement From the National Kidney Foundation Kidney Disease Outcomes Quality Initiative",

author = "{National Kidney Foundation Kidney Disease Outcomes Quality Initiative} and Kramer, {Holly J.} and Jaar, {Bernard G.} and Choi, {Michael J.} and Palevsky, {Paul M.} and Vassalotti, {Joseph A.} and Rocco, {Michael V.}",

note = "Funding Information: This work received support from the National Kidney Foundation . Funding Information: Holly J. Kramer, MD, MPH, Bernard G. Jaar, MD, MPH, Michael J. Choi, MD, Paul M. Palevsky, MD, Joseph A. Vassalotti, MD, and Michael V. Rocco, MD, MSCE. This work received support from the National Kidney Foundation. Dr Kramer reports serving as a consultant for Astra Zeneca and Bayer Pharmaceuticals and is AJKD Engagement Editor. Dr Choi reports receipt of an honorarium from InMed. Dr Palevsky reports serving as a consultant for Janssen Research & Development and is the current President of the NKF. Dr Vassalotti is chief medical officer of the NKF and serves as a consultant for Renalytix, plc. Drs Jaar and Rocco declare that they have no relevant financial interests. Dr Kramer is KDOQI Vice Chair of Commentaries, is on the editorial boards of the Journal of Renal Nutrition and Advances in Chronic Kidney Disease, and served as NKF immediate past-president. Dr Jaar is KDOQI Vice Chair of Education. Dr Choi is KDOQI Vice Chair of Policy. Dr Rocco is KDOQI Chair. Received August 2, 2022, following review and approval by the NKF Scientific Advisory Board (membership listed at https://www.kidney.org/about/sab). Accepted August 8, 2022, after editorial review by a Deputy Editor.",

year = "2022",

month = dec,

doi = "10.1053/j.ajkd.2022.08.004",

language = "English",

volume = "80",

pages = "691--696",

journal = "American Journal of Kidney Diseases",

issn = "0272-6386",

publisher = "W.B. Saunders Ltd",

number = "6",

}

An Endorsement of the Removal of Race From GFR Estimation Equations: A Position Statement From the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. / National Kidney Foundation Kidney Disease Outcomes Quality Initiative.
In: American Journal of Kidney Diseases, Vol. 80, No. 6, 12.2022, p. 691-696.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - An Endorsement of the Removal of Race From GFR Estimation Equations

T2 - A Position Statement From the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

AU - National Kidney Foundation Kidney Disease Outcomes Quality Initiative

AU - Kramer, Holly J.

AU - Jaar, Bernard G.

AU - Choi, Michael J.

AU - Palevsky, Paul M.

AU - Vassalotti, Joseph A.

AU - Rocco, Michael V.

N1 - Funding Information: This work received support from the National Kidney Foundation . Funding Information: Holly J. Kramer, MD, MPH, Bernard G. Jaar, MD, MPH, Michael J. Choi, MD, Paul M. Palevsky, MD, Joseph A. Vassalotti, MD, and Michael V. Rocco, MD, MSCE. This work received support from the National Kidney Foundation. Dr Kramer reports serving as a consultant for Astra Zeneca and Bayer Pharmaceuticals and is AJKD Engagement Editor. Dr Choi reports receipt of an honorarium from InMed. Dr Palevsky reports serving as a consultant for Janssen Research & Development and is the current President of the NKF. Dr Vassalotti is chief medical officer of the NKF and serves as a consultant for Renalytix, plc. Drs Jaar and Rocco declare that they have no relevant financial interests. Dr Kramer is KDOQI Vice Chair of Commentaries, is on the editorial boards of the Journal of Renal Nutrition and Advances in Chronic Kidney Disease, and served as NKF immediate past-president. Dr Jaar is KDOQI Vice Chair of Education. Dr Choi is KDOQI Vice Chair of Policy. Dr Rocco is KDOQI Chair. Received August 2, 2022, following review and approval by the NKF Scientific Advisory Board (membership listed at https://www.kidney.org/about/sab). Accepted August 8, 2022, after editorial review by a Deputy Editor.

PY - 2022/12

Y1 - 2022/12

UR - http://www.scopus.com/inward/record.url?scp=85140617053&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2022.08.004

DO - 10.1053/j.ajkd.2022.08.004

M3 - Comment/debate

C2 - 36058427

AN - SCOPUS:85140617053

SN - 0272-6386

VL - 80

SP - 691

EP - 696

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

IS - 6

ER -